CA
NZ
UK
AU
IND
US
Talphera, Inc. (NASDAQ: TLPH), operating in the pharmaceuticals sector with a marketCapitalizationof $76 million, has reported a net loss of $4.3 million for the second quarter of 2026. The company's financial results come at a key time as its NEPHRO CRRT clinical study of …
Outlook Therapeutics, Inc. (NASDAQ: OTLK) is a biotechnology company with a market capitalization of $206 million, focused on innovative therapies. The company recently reported that it has approximately $11.2 million in cash and cash equivalents as of June 30, 2026. This figure, however, remains …
Sangamo Therapeutics, Inc. (NASDAQ: SGMOQ), a genomic medicine leader specializing in groundbreaking therapeutic technologies, has announced substantial developments following its Chapter 11 filing. The company has successfully concluded asset sales that willYieldapproximately $163.55 million at closing, along with potential future milestone payments that could …
The recent financing move dovetails directly with the FDA clearance of the DeepView System for burn indication, unlocking the ability of the Dallas‑based AI firm to commence commercial sales before year‑end. By securing a $6.5 million non‑dilutive infusion, the company has lifted its cash …
The firm disclosed that its lead candidate GX‑03 will now enroll between 120 and 135 patients in the ongoing Phase 2 study of atopic dermatitis, a move designed to broaden the patient pool and increase the robustness of the trial’s statistical analysis. By expanding …
Spero Therapeutics (NASDAQ: SPRO) is a clinical‑stage biotechnology company valued at $71 million that disclosed a cash balance of $50.8 million as of June 30 2026. This figure excludes the proceeds from a royalty‑backed financing that closed in July 2026, a transaction the firm …
The earnings per share of $0.02 exceeded the consensus estimate of $-0.27, signaling strong competitive positioning.
QT Imaging Holdings, Inc. reported second‑quarter revenue of $7.4 million, representing a 103 % increase over the $3.7 million recorded a year earlier. The surge was driven by the shipment of fifteen Breast Acoustic CT scanners during the quarter, adding to a cumulative total …
With shares currently down 32.7% year-to-date, the financial outlook raises concerns about the broader implications for investor sentiment and market confidence in Sera Prognostics. This performance positions the company in a challenging environment as it seeks to stabilize its financial footing.
STAAR Surgical Co. (NASDAQ: STAA), a leading provider in the medical specialties industry, reported an exceptional second quarter performance, achieving net sales of $93.5 million, which represents a stunning 111% increase compared to the previous year. This surge in revenue showcases the effectiveness of …
Please wait processing your request...